Odronextamab

Odronextamab
Monoclonal antibody
Type	?
Clinical data
Other names	REGN1979; REGN-1979
ATC code	None;
Identifiers
CAS Number	1801338-64-6;
UNII	8R5CM46UIO;

Odronextamab (REGN1979) is a CD20 x CD3 bispecific monoclonal antibody that is developed by Regeneron Pharmaceuticals for B-cell non-Hodgkin lymphoma.^[1]^[2]^[3]^[4]

References[edit]

^ Wei, Joyce; Montalvo-Ortiz, Welby; Yu, Lola; Krasco, Amanda; Olson, Kara; Rizvi, Sahar; Fiaschi, Nathalie; Coetzee, Sandra; Wang, Fang; Ullman, Erica; Ahmed, Hassan Shakil; Herlihy, Evan; Lee, Ken; Havel, Lauren; Potocky, Terra; Ebstein, Sarah; Frleta, Davor; Khatri, Aditi; Godin, Stephen; Hamon, Sara; Brouwer-Visser, Jurriaan; Gorenc, Travis; MacDonald, Doug; Hermann, Aynur; Chaudhry, Aafia; Sirulnik, Andres; Olson, William; Lin, John; Thurston, Gavin; Lowy, Israel; Murphy, Andrew J.; Smith, Eric; Jankovic, Vladimir; Sleeman, Matthew A.; Skokos, Dimitris (9 November 2022). "CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models". Science Translational Medicine. 14 (670): eabn1082. doi:10.1126/scitranslmed.abn1082. PMID 36350988. S2CID 253445866.
^ Bannerji, Rajat; Arnason, Jon E; Advani, Ranjana H; Brown, Jennifer R; Allan, John N; Ansell, Stephen M; Barnes, Jeffrey A; O'Brien, Susan M; Chávez, Julio C; Duell, Johannes; Rosenwald, Andreas; Crombie, Jennifer L; Ufkin, Melanie; Li, Jingjin; Zhu, Min; Ambati, Srikanth R; Chaudhry, Aafia; Lowy, Israel; Topp, Max S (May 2022). "Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial". The Lancet Haematology. 9 (5): e327–e339. doi:10.1016/S2352-3026(22)00072-2. PMC 10681157. PMID 35366963.
^ Bannerji, Rajat; Allan, John N.; Arnason, Jon E.; Brown, Jennifer R.; Advani, Ranjana; Ansell, Stephen M.; O'Brien, Susan M.; Duell, Johannes; Martin, Peter; Joyce, Robin M.; Li, Jingjin; Flink, Dina M.; Zhu, Min; Weinreich, David M.; Yancopoulos, George D.; Sirulnik, Andres; Chaudhry, Aafia; Ambati, Srikanth R.; Topp, Max S. (5 November 2020). "Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy". Blood. 136 (Supplement 1): 42–43. doi:10.1182/blood-2020-136659. S2CID 228809346.
^ Kim, Tae Min; Alonso, Arancha; Prince, Miles; Taszner, Michal; Cho, Seok-Goo; Stevens, Don A.; Poon, Michelle; Lim, Francesca; Le Gouill, Steven; Carpio, Cecilia; Keating, Mary-Margaret; Adriaens, Lieve; Ufkin, Melanie; Sabir, Ayesha; Li, Jingjin; Jankovic, Vladimir; Zhu, Min; Brouwer-Visser, Jurriaan; Leng, Siyang; Sirulnik, L. Andres; Chaudhry, Aafia; Ambati, Srikanth R.; Won Seog, Kim (5 November 2020). "A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma". Blood. 136 (Supplement 1): 28–29. doi:10.1182/blood-2020-136344. S2CID 228841832.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Wei, Joyce; Montalvo-Ortiz, Welby; Yu, Lola; Krasco, Amanda; Olson, Kara; Rizvi, Sahar; Fiaschi, Nathalie; Coetzee, Sandra; Wang, Fang; Ullman, Erica; Ahmed, Hassan Shakil; Herlihy, Evan; Lee, Ken; Havel, Lauren; Potocky, Terra; Ebstein, Sarah; Frleta, Davor; Khatri, Aditi; Godin, Stephen; Hamon, Sara; Brouwer-Visser, Jurriaan; Gorenc, Travis; MacDonald, Doug; Hermann, Aynur; Chaudhry, Aafia; Sirulnik, Andres; Olson, William; Lin, John; Thurston, Gavin; Lowy, Israel; Murphy, Andrew J.; Smith, Eric; Jankovic, Vladimir; Sleeman, Matthew A.; Skokos, Dimitris (9 November 2022). "CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models". Science Translational Medicine. 14 (670): eabn1082. doi:10.1126/scitranslmed.abn1082. PMID 36350988. S2CID 253445866.

[2] Bannerji, Rajat; Arnason, Jon E; Advani, Ranjana H; Brown, Jennifer R; Allan, John N; Ansell, Stephen M; Barnes, Jeffrey A; O'Brien, Susan M; Chávez, Julio C; Duell, Johannes; Rosenwald, Andreas; Crombie, Jennifer L; Ufkin, Melanie; Li, Jingjin; Zhu, Min; Ambati, Srikanth R; Chaudhry, Aafia; Lowy, Israel; Topp, Max S (May 2022). "Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial". The Lancet Haematology. 9 (5): e327–e339. doi:10.1016/S2352-3026(22)00072-2. PMC 10681157. PMID 35366963.

[3] Bannerji, Rajat; Allan, John N.; Arnason, Jon E.; Brown, Jennifer R.; Advani, Ranjana; Ansell, Stephen M.; O'Brien, Susan M.; Duell, Johannes; Martin, Peter; Joyce, Robin M.; Li, Jingjin; Flink, Dina M.; Zhu, Min; Weinreich, David M.; Yancopoulos, George D.; Sirulnik, Andres; Chaudhry, Aafia; Ambati, Srikanth R.; Topp, Max S. (5 November 2020). "Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy". Blood. 136 (Supplement 1): 42–43. doi:10.1182/blood-2020-136659. S2CID 228809346.

[4] Kim, Tae Min; Alonso, Arancha; Prince, Miles; Taszner, Michal; Cho, Seok-Goo; Stevens, Don A.; Poon, Michelle; Lim, Francesca; Le Gouill, Steven; Carpio, Cecilia; Keating, Mary-Margaret; Adriaens, Lieve; Ufkin, Melanie; Sabir, Ayesha; Li, Jingjin; Jankovic, Vladimir; Zhu, Min; Brouwer-Visser, Jurriaan; Leng, Siyang; Sirulnik, L. Andres; Chaudhry, Aafia; Ambati, Srikanth R.; Won Seog, Kim (5 November 2020). "A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma". Blood. 136 (Supplement 1): 28–29. doi:10.1182/blood-2020-136344. S2CID 228841832.

[1]

[2]

[3]

[4]